Sai Parenteral Limited Authorizes Key Managerial Personnel for Regulatory Disclosures
Sai Parenteral Limited has authorized three key managerial personnel - Chairman and Managing Director Anil Kumar Karusala, CFO Anil Kumar, and Company Secretary Shivali Aggarwal - for determining materiality and making regulatory disclosures to stock exchanges. The company notified BSE Limited and NSE on April 06, 2026, in compliance with SEBI Regulation 30(5), ensuring proper governance structure for regulatory communications.
*this image is generated using AI for illustrative purposes only.
Sai Parenteral Limited has notified stock exchanges regarding the authorization of key managerial personnel for regulatory disclosure purposes. The company communicated this development to both BSE Limited and National Stock Exchange of India Limited on April 06, 2026, ensuring compliance with SEBI regulations.
Authorized Personnel Details
Under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has designated three key managerial personnel as authorized persons for determining materiality of events and making disclosures to stock exchanges.
| Sr. No. | Name | Designation |
|---|---|---|
| 1. | Anil Kumar Karusala | Chairman and Managing Director |
| 2. | Anil Kumar | Chief Financial Officer |
| 3. | Shivali Aggarwal | Company Secretary and Compliance Officer |
These authorized persons are severally empowered to determine the materiality of events or information and handle disclosure requirements to stock exchanges on behalf of the company.
Regulatory Compliance
The intimation was formally submitted to the listing departments of both major Indian stock exchanges. BSE Limited, where the company trades under scrip code 544742, and National Stock Exchange of India Limited, where it is listed under the symbol SAIPARENT, received the notification simultaneously.
The communication was digitally signed by Anil Kumar Karusala, Managing Director with DIN 01866646, on April 06, 2026. This authorization framework ensures that the company maintains proper governance structure for regulatory communications and compliance with SEBI's listing obligations.
What strategic initiatives or material events might Sai Parenteral be preparing to disclose that prompted this authorization update?
How could this streamlined disclosure framework impact the company's ability to communicate time-sensitive market developments to investors?
Will this authorization structure enable faster regulatory compliance for potential merger, acquisition, or expansion announcements?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
